Welcome to our dedicated page for Swedish Orphan Biovitrum Ab news (Ticker: BIOVF), a resource for investors and traders seeking the latest updates and insights on Swedish Orphan Biovitrum Ab stock.
The BIOVF news page tracks official announcements and press releases from Swedish Orphan Biovitrum AB (Sobi), a specialised biopharmaceutical company focused on rare and debilitating diseases. Here, readers can follow how Sobi reports progress in haematology, immunology and other specialty indications, as well as corporate actions and collaborations.
Company news often covers clinical trial milestones, such as topline results from pivotal studies. Examples include the XTEND-Kids phase 3 trial of efanesoctocog alfa in children with severe haemophilia A, where Sobi and Sanofi reported that the primary endpoint was met with no factor VIII inhibitors detected, and phase 3 data for avatrombopag in chemotherapy-induced thrombocytopenia. Releases also describe phase 2 and phase 3 programmes like SEL-212 in chronic refractory gout, developed in partnership with Selecta Biosciences.
Investors can also find corporate and financial communications, including invitations to quarterly results presentations, where Sobi outlines its financial reporting schedule and hosts telephone conferences for investors, analysts and media. In addition, the company publishes information on capital management decisions, such as resolutions from the Annual General Meeting and Board decisions to repurchase class C shares used for long-term incentive programmes.
By following BIOVF news, users gain direct access to Sobi’s own descriptions of its research pipeline, partnerships with companies like Sanofi and Selecta Biosciences, and decisions affecting its share capital. This page can be revisited regularly to review new clinical data, regulatory-related updates communicated by the company, and scheduled financial reporting events.
Swedish Orphan Biovitrum (BIOVF) announced that its Board of Directors has authorized the repurchase of all issued class C shares following the Annual General Meeting resolution from May 8, 2025. The repurchase is specifically aimed at fulfilling commitments under the company's long-term incentive programmes.
The repurchase will be conducted at 100% of the quotient value (approximately SEK 0.55 per share) and will occur between July 16 and November 7, 2025. Following the repurchase and conversion of C shares to common shares, Sobi's total holdings of own common shares will increase from 11,377,680 to 12,790,468. The company reported revenue of SEK 26 billion in 2024 and employs approximately 1,900 people globally.
Swedish Orphan Biovitrum AB announced positive results from the XTEND-Kids phase 3 study, demonstrating the safety and efficacy of efanesoctocog alfa in children under 12 with severe hemophilia A. The primary endpoint was successfully met, with no factor VIII inhibitors detected in the 74 participants. Notably, the median annualized bleeding rate was reported at 0.00, indicating effective bleed protection. The study's completion paves the way for regulatory submission in the EU, building on prior successes of the XTEND-1 trial. Efanesoctocog alfa, recently approved in the US, is positioned to potentially redefine the standard of care for hemophilia A.
On October 9, 2020, Swedish Orphan Biovitrum AB (Sobi) announced topline results from a phase 3 study of avatrombopag for chemotherapy-induced thrombocytopenia (CIT). Despite increasing platelet counts compared to placebo, the study did not meet its primary endpoint of preventing platelet transfusions, chemotherapy dose reductions, or delays. In the intent-to-treat population, responder rates were 69.5% for avatrombopag versus 72.5% for placebo (p=0.72). Sobi remains optimistic about avatrombopag's potential benefits and is continuing its focus on other indications, with peak sales estimates unchanged.
On October 22, 2020, at 08:00 CET, Swedish Orphan Biovitrum AB (Sobi™) will release its Q3 2020 report. A teleconference, hosted by CEO Guido Oelkers, will follow at 13:00 CEST for investors and media. The event will be accessible live and thereafter on Sobi's website. Sobi focuses on rare diseases, employing around 1,400 staff across multiple regions. In 2019, Sobi reported a revenue of SEK 14.2 billion. Further details can be found on Sobi’s website.
S Swedish Orphan Biovitrum AB and Selecta Biosciences announced topline results from the phase 2 COMPARE study of SEL-212 for chronic refractory gout. Although SEL-212 demonstrated a higher response rate compared to pegloticase in some endpoints, it did not achieve statistical superiority on the primary endpoint. The study showed a statistically significant greater reduction in serum uric acid levels with SEL-212. Both treatments were well-tolerated, with no deaths reported. The findings suggest SEL-212 could address unmet medical needs and advance to phase 3 trials.
FAQ
What is the current stock price of Swedish Orphan Biovitrum Ab (BIOVF)?
What is the market cap of Swedish Orphan Biovitrum Ab (BIOVF)?
